## VTR: Ventas, Inc. - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.74 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Rep. Gilbert Ray Cisneros, Jr. Buys Ventas, Inc. (NYSE:VTR) Stock**
- Source: MarketBeat | 20251218T101053 | Somewhat-Bullish | Relevance: 100%
- Representative Gilbert Ray Cisneros, Jr. recently purchased between $1,001 and $15,000 worth of Ventas, Inc. (NYSE:VTR) stock on November 12th, as disclosed in a December 15th filing. Ventas reported strong quarterly results, beating EPS expectations and experiencing a 20.5% year-over-year revenue increase, with analysts maintaining a "Moderate Buy" consensus and an average target price of $79.31 despite significant insider selling activity. The company also announced a quarterly dividend of $0.48 per share, though its payout ratio is notably high.

**2. Ventas, Inc. (NYSE:VTR) Receives Consensus Rating of "Moderate Buy" from Analysts**
- Source: MarketBeat | 20251218T080835 | Somewhat-Bullish | Relevance: 100%
- Ventas, Inc. (NYSE:VTR) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year target price of $79.3125. The company recently beat quarterly EPS and revenue estimates, and announced a quarterly dividend of $0.48 per share, despite a high payout ratio. Recent insider selling activity totaling $50.7 million has been noted.

**3. National Health Investors completes $89.2 million in healthcare investments By Investing.com**
- Source: Investing.com Australia | 20251219T000630 | Somewhat-Bullish | Relevance: 63%
- National Health Investors (NYSE:NHI) has invested $89.2 million across four senior housing transactions with an average initial yield of 8.20%, bringing its total investments for 2025 to $392.4 million. The company, a self-managed REIT specializing in senior housing and medical facilities, has seen its shares climb 16.1% year-to-date and is trading near its 52-week high. These investments include acquisitions and mortgage notes for facilities in Pennsylvania, Alabama, South Carolina, and Texas.

**4. Medical Properties Trust (MPW): Evaluating Valuation After Dividend Hike and California Hospital Lease Progress**
- Source: Simply Wall Street | 20251218T041138 | Somewhat-Bullish | Relevance: 63%
- Medical Properties Trust (MPW) recently increased its quarterly dividend by over 12% and signed a new lease for six California hospitals, aiming to reassure investors about cash flow and tenant risk. Despite recent share price fluctuations, MPW shows a positive year-to-date return, suggesting cautious optimism. While analysts expect earnings to recover significantly by 2028, substantial asset impairments and refinancing costs remain key risks to its valuation.

**5. AI, luxury and aging: how Maplewood is rethinking senior living with co-CEOs**
- Source: Stock Titan | 20251218T140222 | Neutral | Relevance: 62%
- Maplewood Senior Living has appointed long-time partners Shane Herlet and Tom Gaston as Co-CEOs, effective December 18, 2025, to lead its new chapter. The company is embracing advanced technology, including AI-driven recruitment and predictive analytics, to address industry challenges in workforce management, operational efficiency, and rising costs. Additionally, Maplewood plans to continue expanding its luxury Inspīr brand, supported by its financial partner Omega Healthcare Investors (OHI), with recent openings like Inspīr Embassy Row and the upcoming five-year anniversary of Inspīr Carnegie Hill.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Keybanc | $85 | $70 | +21% |
| 2025-11-25 | Wells Fargo | $88 | $80 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Keybanc | main | Overweight |
| 2025-11-25 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 17 ($4.24M) |
| Sells | 13 ($23.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 15.7% (+2.5%)
- JPMORGAN CHASE & CO: 12.7% (+102.6%)
- Blackrock Inc.: 11.1% (+2.6%)
- State Street Corpora: 6.2% (+3.3%)
- FMR, LLC: 5.7% (+12.1%)

### Key Risks

1. Heavy insider selling: $23M sold (13 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.74 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +16%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.2B |
| Beta | 0.79 |
| 52W Range | $56.68 - $81.89 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.74 |
| Forward P/E | 140.0 |
| Current P/E | 293.0 |
| YoY Growth | 109.3% |
| EPS Direction | FALLING |

### Technicals

MRS_10 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). RSI neutral at 55. OFD pattern: -MUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.14% (CS: 56) | Neutral |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 1.149x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.11
- **Stop Loss:** $76.15 (3.7% risk)
- **Target:** $82.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 202
- **Position Value:** $15,980.22
- **Portfolio %:** 15.98%
- **Risk Dollars:** $600.00
- **Risk Per Trade:** 0.60%
- **Modifiers:** L1 120% | L2 50% | Combined 0.60x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-11 (Est: $0.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.05 | $0.12 | +141.9% |
| 2025Q2 | $0.14 | $0.15 | +10.4% |
| 2025Q1 | $0.07 | $0.10 | +35.8% |
| 2024Q4 | $0.05 | $0.13 | +156.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*